Report Overview
The Global Cardiac Mapping market is forecast to grow at a CAGR of 9.8%, reaching USD 2.51 billion in 2031 from USD 1.57 billion in 2026.
Highlights:
- 1Cardiologists performing precise arrhythmia mappingSpecialists are using advanced systems for accurate diagnosis and treatment planning.
- 2Hospitals upgrading electrophysiology laboratoriesFacilities are installing high-resolution mapping tools for complex procedures.
- 3Surgeons conducting real-time ablation guidanceTeams are applying mapping technologies during catheter-based interventions.
- 4Clinics adopting diagnostic mapping cathetersProviders are integrating systems for improved patient monitoring and outcomes.
- 5Medical teams treating atrial fibrillation casesDoctors are leveraging mapping for effective rhythm disorder management.
- 6Researchers developing enhanced mapping solutionsInnovators are advancing technologies for better cardiac visualization and accuracy.
Cardiac mapping is the study of electrophysiology, or EP. The cardiac mapping process helps in identifying various types of temporal and spatial distribution in the heart. This system also helps in accurately recognizing various sites of abnormal rhythm and delivers radio-frequency catheter ablation therapy. The increasing global prevalence of cardiovascular diseases is the major factor propelling this market’s growth during the forecasted timeline. Similarly, technological advancements in cardiac mapping devices are also estimated to propel market expansion. New and effective techniques for the successful treatment of atrial fibrillation are offering market players valuable opportunities to enhance their competitive position and accelerate overall market growth.
Cardiac Mapping Market Overview:
The global cardiac mapping market is segmented by:
Product: By product, the global cardiac mapping market is categorized into EP ablation catheters, EP laboratory devices, EP diagnostic catheters, and access devices. The EP ablation catheter category is estimated to grow significantly.
Indication: By indication, the market is divided into Atrial Fibrillation, Atrial Flutter, Atrioventricular Nodal Reentry Tachycardia, and Wolff-Parkinson-White syndrome. The Atrial Flutter category is forecasted to grow rapidly.
End-User: The end-user segment of the cardiac mapping market is divided into hospitals & clinics and diagnostic centers. The hospitals and clinics category is estimated to grow significantly due to the increasing governmental investment in the development of the hospital infrastructure.
Region: The Asia Pacific region is estimated to increase its share over the forecast period due to the initiatives being taken and the investment being made to develop the medical infrastructure in countries such as India to provide better healthcare facilities.
Top Trends Shaping the Cardiac Mapping Market:
1. Growth of the healthcare infrastructure
The growing global advancements in healthcare infrastructure and the introduction of significant governmental policies are key factors driving the demand to develop cardiac mapping systems.
2. Increasing awareness of early disease detection
The increasing individual awareness of early diagnosis is also estimated to boost the demand for cardiac mapping systems. The cardiac mapping system helps detect various types of cardiovascular disease, including arrhythmias and coronary artery disease.
Cardiac Mapping Market Growth Drivers vs. Challenges:
Opportunities:
Growing global cases of cardiovascular diseases: The major factor propelling the growth of the cardiac mapping market during the forecasted timeline is the increasing global prevalence of cardiovascular diseases. The cases of cardiovascular diseases, like arrhythmias, heart attacks, and coronary artery disease, witnessed a major increase. The Centers for Disease Control and Prevention of the USA, in its report, stated that in 2022, the total cases of cardiovascular diseases were recorded at 702,880.
Rising technological advancements: The increasing advancement in medical technology and the accuracy and efficiency of cardiac mapping systems are estimated to grow, raising their demand.
Challenges:
Higher cost of cardiac mapping procedure: The higher cost of cardiac mapping procedures is among the major factors challenging the cardiac mapping market growth during the estimated timeline.
Cardiac Mapping Market Regional Analysis:
North America: The North American region is estimated to hold a significant share over the forecast period due to the well-established healthcare industry and the availability of quality healthcare services, coupled with the early adoption of advanced and enhanced medical devices and detection products, which are being made available to the market players. In addition, the growing geriatric population and the increased risk of heart problems are among other reasons for the rising demand for cardiac mapping in countries such as the US.
Cardiac Mapping Market Competitive Landscape:
The market is fragmented, with many notable players including Biosense Webster, Inc., Medtronic, Abbott, BIOTRONIK SE & Co KG, Acutus Medical, Boston Scientific Corporation, AMETEK Inc., Catheter Precision Inc., Medical Device Business Services, Inc. (Johnson&Johnson), MicroPort Scientific Corporation, Koninklijke Philips N.V, and Kardium Inc., among others.
Product Launch: In October 2024, Boston Scientific Corporation, a global leader in the biotechnology market, launched a next-generation cardiac mapping system, FARAPULSE Pulsed Field Ablation System. The system provides visualization for cardiac ablation procedures.
Cardiac Mapping Market Developments:
January 2026: Medtronic announced CE Mark approval in Europe for the Affera™ Sphere-360™ catheter, an integrated cardiac mapping and pulsed field ablation system, alongside first U.S. IDE trial cases for atrial fibrillation treatment.
December 2025: Vektor Medical received FDA 510(k) clearance for next-generation vMap® technology, adding atrial flutter mapping, enhanced ECG streaming, 3D model integration, and software-based cardiac mapping deployment capabilities.
November 2025: Volta Medical and GE HealthCare launched integrated AF-Xplorer™ II and CardioLab™ AltiX AI.i electrophysiology solutions in the United States, enhancing AI-assisted cardiac mapping and atrial fibrillation ablation workflows.
October 2025: Kardium completed its first commercial procedures using the Globe® Pulsed Field System, integrating high-density cardiac mapping and pulsed-field ablation technology for advanced atrial fibrillation treatment procedures.
July 2025: Stereotaxis received U.S. FDA clearance for the MAGiC Sweep™ catheter, the first robotically navigated high-density electrophysiology mapping catheter for detailed cardiac arrhythmia mapping procedures.
May 2025: CoreMap, Inc. secured U.S. FDA IDE approval for its INvENI clinical study evaluating the CoreMap™ Endocardial Electrophysiology Mapping System for persistent and long-standing persistent atrial fibrillation patients.
Cardiac Mapping Market Scope:
| Report Metric | Details |
|---|---|
| Total Market Size in 2026 | USD 1.57 billion |
| Total Market Size in 2031 | USD 2.51 billion |
| Forecast Unit | Billion |
| Growth Rate | 9.8% |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Product, Indication, End-user, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|
Cardiac Mapping Market Segmentation:
By Product
EP Ablation Catheters
EP Laboratory Devices
EP Diagnostic Catheters
Access Devices
By Indication
Atrial Fibrillation
Atrial Flutter
Atrioventricular Nodal Re-entry Tachycardia
Wolff-Parkinson-White Syndrome
By End-User
Hospitals and Clinics
Diagnostic Centers
By Region
North America
Europe
Asia Pacific
South America
Middle East & Africa
Market Segmentation
By Product
By Indication
By End-user
By Geography
Table of Contents
1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. GLOBAL CARDIAC MAPPING MARKET BY PRODUCT
5.1. Introduction
5.2. EP Ablation Catheters
5.3. EP Laboratory Devices
5.4. EP Diagnostic Catheters
5.5. Access Devices
6. GLOBAL CARDIAC MAPPING MARKET BY INDICATION
6.1. Introduction
6.2. Atrial Fibrillation
6.3. Atrial Flutter
6.4. Atrioventricular Nodal Re-entry Tachycardia
6.5. Wolff-Parkinson-White Syndrome
7. GLOBAL CARDIAC MAPPING MARKET BY END-USER
7.1. Introduction
7.2. Hospitals and Clinics
7.3. Diagnostic Centers
8. GLOBAL CARDIAC MAPPING MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Product
8.2.2. By Indication
8.2.3. By End-User
8.2.4. By Country
8.2.4.1. USA
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. By Product
8.3.2. By Indication
8.3.3. By End-User
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. By Product
8.4.2. By Indication
8.4.3. By End-User
8.4.4. By Country
8.4.4.1. United Kingdom
8.4.4.2. Germany
8.4.4.3. France
8.4.4.4. Spain
8.4.4.5. Others
8.5. Middle East and Africa
8.5.1. By Product
8.5.2. By Indication
8.5.3. By End-User
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.2. UAE
8.5.4.3. Others
8.6. Asia Pacific
8.6.1. By Product
8.6.2. By Indication
8.6.3. By End-User
8.6.4. By Country
8.6.4.1. China
8.6.4.2. Japan
8.6.4.3. India
8.6.4.4. South Korea
8.6.4.5. Taiwan
8.6.4.6. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Biosense Webster, Inc.
10.2. Medtronic
10.3. Abbott
10.4. BIOTRONIK SE & Co. KG
10.5. Acutus Medical
10.6. Boston Scientific Corporation
10.7. AMETEK Inc.
10.8. Catheter Precision Inc.
10.9. Medical Device Business Services, Inc. (Johnson & Johnson)
10.10. MicroPort Scientific Corporation
10.11. Koninklijke Philips N.V.
10.12. Kardium Inc.
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
Navigate
Trusted by the world's leading organizations











